Description
In the Spring of 2003, Kalorama published its first report on Outsourcing in Drug Discovery. Since then, so much has changed, the use of the term “2nd Edition” hardly seems appropriate. This new study involved completely re-examining the market from the ground up.
This new report is designed to make readers aware of the enormous changes that are taking place in the drug discovery outsourcing market, and the forces that are shaping the sector. It presents viewpoints from both customers and suppliers. Segments, size, and growth of the market are presented. The trend toward the increased use of offshore suppliers is covered in detail. The report also provides profiles of 30 suppliers, representative of those active in this market.
Segments covered in this report include:
- Chemistry Services
- Building Blocks
- Compound Synthesis
- Libraries
- Process Research
- Other Services
- Biology Services
- Protein Expression
- Structural Analysis
- Target Validation
- Pathways Analysis
- Other Services
- Screening Services
- Assay Development
- Primary Screening
- Secondary Screening
- Lead Optimization
- Early ADMET
- Analogues Creation
- Computational Support
- Other services
In addition to market data and forecasts, the report covers issues such as
- What factors should a client consider when deciding whether to do a project in-house or outsource it?
- Is it in his best interest to seek a domestic outsourcing partner, or go with an overseas supplier?
- How does he select the CRO that is best for him?
- What are the best practices when working with a CRO?
- How do you measure his effectiveness?
- How do you avoid problems with your CRO?
- How do you maximize benefits?
Offshoring, not such an issue in 2003, has become a major concern for domestic suppliers and clients alike. This report looks at offshore at outsourcing suppliers based in three major areas: India, China, and Eastern Europe. The relative advantages each country provides are contrasted with some of their limitations. The report asses which projects are moving to which suppliers and why. Examples of successful CROs from each geographic area are cited. Big pharma strategies for offshoring are examined.
Table of Contents
Chapter One: Executive Summary
- Why Outsourcing?
- Outsourcing in Drug Discovery: 2003 View
- The Flat World of the 21st Century
- India, Fiberoptics, and Y2K.
- China, WTO & Japan.
- Russia and Boeing.
- VCs Promote Outsourcing.
- Globalization in Drug Discovery: View in 2005
- Environment & Expectations
- Wall Street’s View of CROs
- Public Hot-Buttons
- Strategic Questions
- Future Expectations
- Report Objectives & Structure
- Results Summary
- Observations on the Market
- Key Issues & Answers
- What are the factors shaping the drug discovery outsourcing market?
- What are the major types of drug discovery services and which are growing fastest?
- What are the implications of offshoring for this market?
- What do customers look for in a supplier?
- What do suppliers do to make themselves successful?
- Who are the leaders in this market? Who are some promising newcomers?
- How large is the market and how fast is it growing?
Chapter Two: Outsourcing Issues
- The Outsourcing Decision
- Questions Company Must Answer
- Decision Criteria:
- Geographic Considerations
- Overseas Advantages & Limitations
- Advantages for U.S.-based CROs
- Academic vs. Commercial CRO
- How to Select a CRO
- Factors Driving the CRO Selection Decision:
- Negotiating the Deal
- Working with Your CRO
- Elements of the Contract
- How to Help Your CRO and Head Off Problems
- Effective Alliance Management
- Measuring Effectiveness of a Deal
- Examples of Successful Deals
- Product Supply Contract
- Fee-for-Service and Full-Time Equivalent (FTE)
- Collaborative Research Agreement
- Non-Exclusive Alliance
- Exclusive Strategic Alliance
Chapter Three: Offshoring
- Overview
- Viewpoints
- Pharmas and Offshoring
- The Draw of Asia Pacific for Big Pharma
- Investing in Asia
- Russia & Eastern Europe
- Why Russia?
- ChemBridge
- Chemical Diversity (ChemDiv)
- Q&A on Russian CROs
- What Is It Like in Moscow?
- How Is Doing Business There?
- What Are the Barriers to Integration?
- What Are the Issues Regarding Language?
- What Are the Relative Strengths of Russia, China, and India in Outsourcing?
- India
- Opportunities in India
- India’s IP and Regulatory Environment
- Indian CROs
- Bottom line
- Clinical Trials in India
- China, Taiwan, Korea
- China’s Advantages & Limitations
- The Chinese Market
- Shanghai Bio-Explorer Inc.
- Invitrogen in China
- Roche Sets up New R&D Center in Shanghai
- TargeGen and Their WuXi Relationship
- Taiwan and TaiGen
- Korea and Crystal Genomics
Chapter Four: Outsourcing from the Customer Side
- Perspectives of Pharmas
- Preclinical Outsourcing at Amgen
- GlaxoSmithKline Outsources Early Drug Discovery
- Merck Partners for New Research
- Pfizer Sources Discovery Chemistry
- Purdue Pharma’s Offshoring Experience
- TargeGen: a Small Pharma’s View of Outsourcing
- What Customers Seek in a CRO
- Selection Criteria
- Keys to Outsourcing Success
- What Pharma Spends
- What the Pharma Industry Spends on R&D
- What Pharma Spends on Outsourcing
- Manufacturing
- Clinical & Pre-clinical Research
- Clinical Trials
- Drug Discovery
Chapter Five: Outsourcing from the Supplier Side
- Supplier Model
- Albany’s Success Formula
- J-Star’s On-Shore Advantage
- Cyprotex Takes the Lead
- Pre-Pharma Model
- Ricerca’s One-Stop-Shop
- Pharmacopeia Reinvents Itself
- MerLion Springs from Nature
- Partnering Model
- FSMA Collaboration with deCODE Chemistry—Outsourcing It All
- Building a Bridge to China
- Medarex’ Rx for Success
- Successful Suppliers’ Strategies
- What business are we in and what business do we want to be in?
- How does my unique technology become a market opportunity?
- What services will we provide?
- How will we attract and sell customers?
- What should we do to make sure the assignment is successful?
Chapter Six: Markets for Outsourcing Services
- Chemistry Services Markets
- Chemistry Outsourcing Rationale
- Types of Chemistry Services and Suppliers
- Leading Suppliers
- Market Size & Projected Growth
- Biology Services Markets
- Rise of Biology Services
- Types of Biology Services
- Suppliers and Technologies
- Market Size & Projected Growth
- Screening Services Markets
- Role of Outsourcing in HTS
- Screening Services
- Screening Services Suppliers
- Market Size & Growth
- Lead Optimization Services Markets
- Early ADME/Tox
- Compound Analogues and SAR
- Lead-Opt Service Suppliers
- Market Size & Growth
Chapter Seven: Supplier Profiles
- Overview
- Albany Molecular Research, Inc.
- Company History & Structure
- Financials
- Drug Discovery Services
- Outsourcing Relationships
- ASINEX
- Company History & Focus
- Services Provided
- Step-by-Step drug discovery … the ASINEX way
- Clients
- Bridge Pharmaceuticals
- Concept
- Company Overview
- Future Expectations
- Cardinal Health PTS (formerly Magellan Laboratories)
- Company History & Structure
- Financials
- Drug Discovery & Development Services
- Strategic Relationships
- ChemBridge & CRL
- Company Structure & Focus
- Drug Discovery Products & Services
- Outsourcing Relationships
- Charles River Laboratories
- History & Focus
- Financials
- PreClinical Services
- Chembiotek Research International
- Ownership & Focus
- Chemistry & Biology Research Services
- Chemical Diversity
- Company History & Focus
- Drug Discovery Services
- Customers
- ComGenex Inc.
- Company History & Focus
- Drug Discovery Services
- Outsourcing Research Partners
- Cyprotex
- Company History and Focus
- Financials
- Technologies and Services
- Future
- deCODE Genetics
- Company Focus & Objectives
- Discovery Partners International
- Company History & Acquisitions
- Financials
- Drug Discovery Services
- Outsourcing Partners
- Dr. Reddy’s
- Company History & Structure
- Financials
- Business Segments
- Custom Pharmaceutical Services
- Future of CRS
- Evotec OAI
- Company History & Structure
- Financials
- Drug Discovery Services
- Outsourcing Partners
- GVK Biosciences
- Corporate Overview
- Research Services
- GVK Future
- J-Star
- Company and Focus
- Projects and Services
- Unique Expertise
- Johnson Matthey Pharma Services (formerly Pharm-Eco)
- Company History & Focus
- Financials
- Drug Discovery Services
- Jubilant Organosys Ltd.
- Jubilant Corporation
- Jubilant Biosys
- Jubilant Organosys
- Future
- Key Organics
- History & Focus
- Businesses: Products & Services
- Outsourcing Services
- Company Advantages
- MDS Pharma Services
- Company History & Structure
- Financials
- Drug Discovery Services
- Overseas Initiatives
- Outsourcing Research Partners
- Medarex, Inc.
- Company Focus & Objectives
- Financials
- Drug Discovery Services
- Outsourcing Research Partners
- Medicilon
- Company & Focus
- Drug Discovery and Development Services Provided
- MerLion Pharmaceuticals
- Company Background & Objectives
- Drug Discovery Services
- Outsourcing Research Parnters
- NovaScreen
- Company Focus
- Contract Services
- Caliper Acquires NovaScreen
- Pharmacopeia
- Company History & Focus
- Financials
- Drug Discovery Services
- Research Partners
- PharmaCore
- Company Focus
- Drug Discovery Services
- Outsourcing Research Partners
- PPD, Inc.
- Company Focus
- Financials
- Drug Discovery Services
- Outsourcing Research Partners
- Ricerca Biosciences LLC
- Company Focus
- Outsourcing Services
- Future
- Scynexis
- Company Capabilities & Focus
- Customers
- Description of Services Offered
- Future Looks Bright
- WuXi Pharma Tech
- Background & Strategy
- WuXi Range of Services
- Customer Comments
Appendix: Company Directory
List of Exhibits
Chapter One: Executive Summary
- Table 1-1: Projected Revenues by Market Segment (Chemistry, Biology,
- Screening, Lead Optimization) 2005-2009 Table 1-2: Leading Suppliers by Market Segment
Chapter Two: Outsourcing Issues
- Table 2-1: CRO vs. Academia A Comparison of Potential Partners
- Table 2-2: Why Deals Succeed and Why Deals Fail Factors in Success, Reasons for Failure, and Alliance Outcome Stats
Chapter Three: Offshoring
- Table 3-1: Outsourcing in India vs. China (Market Opportunities, Business Issues, Scientist Issues)
Chapter Four: Outsourcing from the Customer Side
- Figure 4-1: GlaxoSmithKline Productivity/Cost Supplier Evaluation Matrix
- Table 4-1: Different Criteria in Pfizer’s API and Discovery Chemistry Sourcing Table 4-2: CRO Capabilities Checklist
- Table 4-3: CRO Sourcing Options in Chemistry
- Table 4-4: Dos and Don’ts for Suppliers
- Table 4-5: Pharma Industry R&D Expenditures In-House vs.
- Outsourced 1997, 2001, 2005, 2009
- Table 4-6: Outsourced Drug Discovery and Development Expenditures by Type (Discovery vs. Clinical Trials) 1997, 2001, 2005, 2009
Chapter Five: Outsourcing from the Supplier Side
- Table 5-1: Suppliers by Types of Services Provided Chemistry, Biology,
- Lead Opt, Full Service
Chapter Six: Markets for Outsourcing Services
- Table 6-1: Chemistry Services Market (Revenues, Annual Growth, and Share of Outsourced Drug Discovery Market) 2005-2009
- Table 6-2: Sales by Chemistry Market Segment (Building Blocks, Compound Synthesis, Libraries, Process Research, and Other Services) 2005
- Table 6-3: Biology Services Market (Revenues, Annual Growth, and Share of Outsourced Drug Discovery Market) 2005-2009
- Table 6-4: Sales by Biology Market Segment (Protein Expression, Structural Analysis, Target Validation, Pathways Analysis, and Other Services) 2005
- Table 6-5: Screening Services Market (Revenues, Annual Growth, and Share of Outsourced Drug Discovery Market) 2005-2009
- Table 6-6: Sales by Screening Market Segment (Assay Development, Primary Screening, Secondary Screening) 2005
- Table 6-7: Lead Optimization Services Market (Revenues, Annual Growth, and Share of Outsourced Drug Discovery Market) 2005-2009
- Table 6-4: Sales by Lead Optimization Market Segment (Early ADMET, Create Analogues, Computational Support, and Other Services) 2005
Chapter Seven: Supplier Profiles
- Table 7-1: Growth and Profitability Characteristics of Selected Contract Drug Discovery Companies by Company Size
- Table 7-2: Summary of Suppliers Profiled (Location, Year Founded, Revenues, Services, Number of Employees, Number of Clients)
- Table 7-3: Charles River Laboratories Sales by Segment (Research Models & Service, Preclinical Services, Clinical Services) First 9 Months of 2005 and Change of 2004
- Table 7-4: Applications for Cyprotex’s Cloe in Various Stages of Discovery
